The Görlich Family Office thinks and acts across generations. We manage assets critically – ready to preserve, rethink and dare to try something new. Our experience with investment funds in the real estate segment helps us to invest in other economic sectors such as biotech. We recognize entrepreneurial opportunities – for our family and for our clients.
We always invest together with our clients. Our investors are experienced in equity investments and can cope with risks. We ourselves have experienced entrepreneurial successes and setbacks. We look to the future with respect and discipline, but also with a willingness to take risks.
Biotechnology is revolutionizing medicine. With our fund company, we are the lead investor in 4TEEN4 Pharmaceuticals GmbH and offer investors a stake in this enterprise. This company is developing a drug against cardiogenic shock and a biomarker for early detection. Success would save the lives of hundreds of thousands of people worldwide every year.
Our vision: to give semi-professional and professional investors access to this technology of the future.
4TEEN4 Pharmaceuticals, a German biotech start-up, is looking to raise EUR 50m to fund further clinical trials, CEO Andreas Bergmann told Mergermarket. The company has […]
Die Görlich Gruppe investiert in ein Biotech-Unternehmen. Um weitere Investoren daran zu beteiligen, legt das Single Family Office einen Spezialfonds auf, der aktuell bereits 20 […]
Lange war es eher ruhig in der Herzforschung. Viele Entwicklungen der letzten Jahrzehnte richteten sich weniger auf die Heilung schwerwiegender Herzkrankheiten als auf die Optimierung […]
Die Biotech-Branche erlebt einen Boom. Das Family Office Görlich Gruppe hat zusammen mit dem Biotech-Startup 4teen4 Pharmaceuticals einen Fonds aufgelegt, der ausschließlich in ein Biotech-Unternehmen […]
Die Firma 4Teen4 entwickelt ein Mittel, das Patienten vor dem Tod durch Organversagen nach einem Herzinfarkt bewahren soll – ein Milliardenmarkt. Bei der Arbeit von […]